TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Kadimastem ( (IL:KDST) ) is now available.
Kadimastem Ltd has announced a significant licensing agreement with NLS Pharmaceuticals Ltd. This deal is expected to impact Kadimastem’s business activities, potentially aiding in capital raising efforts and enhancing their market positioning.
More about Kadimastem
YTD Price Performance: 48.62%
Average Trading Volume: 15,684
Current Market Cap: ILS74.9M
See more insights into KDST stock on TipRanks’ Stock Analysis page.